LLYHealthcare · Drug Manufacturers - General

Eli Lilly and Company

DeepValues Research covers Eli Lilly and (LLY) with 2 research reports since Feb 15, 2026. The latest Deep Value Intelligence report (Mar 31, 2026) ends with a Neutral stance (3.28/5). Sector: Healthcare · Drug Manufacturers - General.

Latest stanceNeutral3.28Mar 31, 2026

Reports2since Feb 15, 2026

Latest reportMar 31, 2026EN

Research timeline

Mar 31, 2026

Deep Value Intelligence
Eli Lilly and Company (LLY) Deep Value Intelligence Report
Neutral (3.28/5) on Eli Lilly and (LLY), Mar 31, 2026. Price $920. - Eli Lilly is an exceptional pharmaceutical business currently experiencing a rare…

Neutral3.28EN33 min
Feb 15, 2026

Deep Value Intelligence
Eli Lilly and Company (LLY) Deep Value Intelligence Report
Deep Value Intelligence report on Eli Lilly and (LLY), Feb 15, 2026. LLY is in a "prove-it" phase. The long-term outlook is exceptional, but the…

EN34 min

Compare with other Healthcare companies

All Healthcare stocks

Company	Industry	Latest stance	Price · value	Date	Reports
LLYEli Lilly and	Drug Manufacturers - General	Neutral3.28	$920	2026-03-31	2
JNJJohnson & Johnson	Drug Manufacturers - General	Neutral3.08	$264 · $184	2026-10-13	3
ABBVAbbVie	Drug Manufacturers - General	Bullish2.35	$257 · $151	2026-09-13	11
AZNAstraZeneca	Drug Manufacturers - General	Bullish3.33	$161 · $198	2026-08-08	1
GRDN	Medical Care Facilities	Bearish3.16	$40 · $14	2026-10-12	1
ALLOAllogene Therapeutics	Biotechnology	Bearish3.10	$1	2026-10-07	1
MRNA	Biotechnology	Neutral3.01	$199 · $448	2026-09-27	1
CRSPCRISPR Therapeutics	Biotechnology	Neutral2.30	$56	2026-09-23	1
INSMInsmed	Biotechnology	Bearish2.52	$118	2026-09-23	1

Charts from the latest report

Open report